Development of High-Throughput Screening Assays for Influenza

Combating the Threat of Pandemic Influenza: Drug Discovery Approaches

Volumn , Issue , 2007, Pages 38-72

  Noah, Diana L ^a   White, E Lucile ^a   Noah, James W ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Hemagglutination inhibition (HAI) assay; HTS antiviral screening using primary assay; Influenza HTS assay development

Indexed keywords

EID: 67651215764     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470179727.ch2     Document Type: Chapter

References (121)

1. Kiselar, J. G.; Downard, K. M. Antigenic surveillance of the influenza virus by mass spectrometry. Biochemistry 1999, 38, 14185-14191.
2. Thompson, W. W.; Shay, D. K.; Weintraub, E.; Brammer, L.; Bridges, C. B.; et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292, 1333-1340.
3. Thompson, W. W.; Shay, D. K.; Weintraub, E.; Brammer, L.; Cox, N.; et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289, 179-186.
4. Szucs, T. The socio-economic burden of influenza. J. Antimicrob. Chemother. 1999, 44 Suppl. B, 11-15.
5. Meltzer, M. I.; Cox, N. J.; Fukuda, K. The economic impact of pandemic influenza in the United States: Priorities for intervention. Emerg. Infect. Dis. 1999, 5, 659-671.
6. Meltzer, M. I.; Bridges, C. B. Economic analysis of influenza vaccination and treatment. Ann. Intern. Med. 2003, 138, 608; author reply 608-609.
7. Phipps, L. P.; Essen, S. C.; Brown, I. H. Genetic subtyping of influenza A viruses using RT-PCR with a single set of primers based on conserved sequences within the HA2 coding region. J. Virol. Methods 2004, 122, 119-122.
8. United States Department of Agriculture. http://www.ars.usda.gov/Research/docs.htm?docid=11425. 2006.
9. Vahlenkamp, T. W.; Harder, T. C. Influenza virus infections in mammals. Berl. Munch. Tierarztl. Wochenschr. 2006, 119, 123-131.
10. Olsen, B.; Munster, V. J.; Wallensten, A.; Waldenstrom, J.; Osterhaus, A. D.; et al. Global patterns of influenza a virus in wild birds. Science 2006, 312, 384-388.
11. United States Department of Health and Human Services. http://www.pandemicflu.gov/issues/screening.html. 2006.
12. Layne, S. P. Human influenza surveillance: the demand to expand. Emerg. Infect. Dis. 2006, 12, 562-568.
13. von Itzstein, M.; Wu, W. Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Van Phan, T.; Smythe, M. L.; White, H. F.; Oliver, S. W.; et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363, 418-423.
14. Hao, W.; Herlihy, K. J.; Zhang, N. J.; Fuhrman, S. A.; Doan, C.; Patick, A. K.; Duggal, R. Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening. Antimicrob. Agents. Chemother. 2007, 51, 95-102.
15. Kleymann, G.; Werling, H. O. A generally applicable, high-throughput screening-compatible assay to identify, evaluate, and optimize antimicrobial agents for drug therapy. J. Biomol. Screen. 2004, 9, 578-587.
16. Steinhauer, D. A.; Skehel, J. J. Genetics of influenza viruses. Annu. Rev. Genet. 2002, 36, 305-332.
17. Hampson, A. W.; Mackenzie, J. S. The influenza viruses. Med. J. Aust. 2006, 185, S39-S43.
18. Stevens, J.; Blixt, O.; Tumpey, T. M.; Taubenberger, J. K.; Paulson, J. C.; et al. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 2006, 312, 404-410.
19. Nayak, D. P.; Hui, E. K.; Barman, S. Assembly and budding of influenza virus. Virus Res. 2004, 106, 147-165.
20. Noah, D. L.; Krug, R. M. Influenza virus virulence and its molecular determinants. Adv. Virus Res. 2005, 65, 121-145.
21. Bruns, K.; Studtrucker, N.; Sharma, A.; Fossen, T.; Mitzner, D.; et al. Structural characterization and oligomerization of PB1-F2, a pro-apoptotic influenza A virus protein. J. Biol. Chem. 2006.
22. Lee, M. T.; Klumpp, K.; Digard, P.; Tiley, L. Activation of influenza virus RNA polymerase by the 5' and 3' terminal duplex of genomic RNA. Nucleic Acids Res. 2003, 31, 1624-1632.
23. Spector, R.; Vesell, E. S. The heart of drug discovery and development: rational target selection. Pharmacology 2006, 77, 85-92.
24. Cattoli, G.; Capua, I. Molecular diagnosis of avian influenza during an outbreak. Dev. Biol. (Basel) 2006, 124, 99-105.
25. Stevens, J.; Blixt, O.; Paulson, J. C.; Wilson, I. A. Glycan microarray technologies: Tools to survey host specificity of influenza viruses. Nat. Rev. Microbiol. 2006, 4, 857-864.
26. Wiley, D. C.; Skehel, J. J. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem. 1987, 56, 365-394.
27. Huang, Q.; Sivaramakrishna, R. P.; Ludwig, K.; Korte, T.; Bottcher, C.; et al. Early steps of the conformational change of influenza virus hemagglutinin to a fusion active state: Stability and energetics of the hemagglutinin. Biochim. Biophys. Acta 2003, 1614, 3-13.
28. Park, H. E.; Gruenke, J. A.; White, J. M. Leash in the groove mechanism of membrane fusion. Nat. Struct. Biol. 2003, 10, 1048-1053.
29. Kido, H.; Yokogoshi, Y.; Sakai, K.; Tashiro, M.; Kishino, Y.; et al. Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J. Biol. Chem. 1992, 267, 13573-13579.
30. Cross, K. J.; Wharton, S. A.; Skehel, J. J.; Wiley, D. C.; Steinhauer, D. A. Studies on influenza haemagglutinin fusion peptide mutants generated by reverse genetics. EMBO J. 2001, 20, 4432-4442.
31. Nayak, D. P.; Reichl, U. Neuraminidase activity assays for monitoring MDCK cell culture derived influenza virus. J. Virol. Methods 2004, 122, 9-15.
32. Matrosovich, M. N.; Matrosovich, T. Y.; Gray, T.; Roberts, N. A.; Klenk, H. D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 2004, 78, 12665-12667.
33. Fornabaio, M.; Cozzini, P.; Mozzarelli, A.; Abraham, D. J.; Kellogg, G. E. Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 2. Computational titration and pH effects in molecular models of neuraminidase-lnhibitor complexes. J Med. Chem. 2003, 46, 4487-4500.
34. Russell, R. J.; Haire, L. F.; Stevens, D. J.; Collins, P. J.; Lin, Y. P.; et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006, 443, 45-49.
35. Mungall, B. A.; Xu, X.; Klimov, A. Assaying susceptibility of avian and other influenza A viruses to zanamivir: Comparison of fluorescent and chemiluminescent neuraminidase assays. Avian Dis. 2003, 47, 1141-1144.
36. Regoes, R. R.; Bonhoeffer, S. Emergence of drug-resistant influenza virus: Population dynamical considerations. Science 2006, 312, 389-391.
37. Kiso, M.; Mitamura, K.; Sakai-Tagawa, Y.; Shiraishi, K.; Kawakami, C.; et al. Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. Lancet 2004, 364, 759-765.
38. de Jong, M. D.; Tran, T. T.; Truong, H. K.; Vo, M. H.; Smith, G. J.; et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 2005, 353, 2667-2672.
39. Gupta, R. K.; Nguyen-Van-Tam, J. S. Oseltamivir resistance in influenza A (H5N1) infection. N. Engl. J. Med. 2006, 354, 1423-1424.
40. Pinto, L. H.; Lamb, R. A. Viral ion channels as models for ion transport and targets for antiviral drug action. FEBS Lett. 2004, 560, 1-2.
41. Bright, R. A.; Shay, D. K.; Shu, B.; Cox, N. J.; Klimov, A. I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006, 295, 891-894.
42. Kandun, I. N.; Wibisono, H.; Sedyaningsih, E. R.; Yusharmen; Hadisoe-darsuno, W.; et al. Three Indonesian clusters of H5N1 virus infection in 2005. N. Engl. J. Med. 2006, 355, 2186-2194.
43. Ozaki, T.; Yauchi, M.; Xin, K. Q.; Hirahara, F.; Okuda, K. Cross-reactive protection against influenza A virus by a topically applied DNA vaccine encoding M gene with adjuvant. Viral Immunol. 2005, 18, 373-380.
44. Saldanha, S. A.; Kaler, G.; Cottam, H. B.; Abagyan, R.; Taylor, S. S. Assay principle for modulators of protein-protein interactions and its application to non-ATP-competitive ligands targeting protein kinase A. Anal. Chem. 2006, 78, 8265-8272.
45. Jeon, S. H.; Kayhan, B.; Ben-Yedidia, T.; Arnon, R. A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin. J. Biol. Chem. 2004, 279, 48410-48419.
46. Boulo, S.; Akarsu, H.; Ruigrok, R. W.; Baudin, F. Nuclear traffic of influenza virus proteins and ribonucleoprotein complexes. Virus Res. 2007, 124, 12-21.
47. Hooker, L.; Sully, R.; Handa, B.; Ono, N.; Koyano, H.; et al. Quantitative analysis of influenza virus RNP interaction with RNA cap structures and comparison to human cap binding protein eIF4E. Biochemistry 2003, 42, 6234-6240.
48. Fechter, P.; Brownlee, G. G. Recognition of mRNA cap structures by viral and cellular proteins. J. Gen. Virol. 2005, 86, 1239-1249.
49. De Gregorio, E.; Preiss, T.; Hentze, M. W. Translational activation of uncapped mRNAs by the central part of human eIF4G is 5' end-dependent. RNA 1998, 4, 828-836.
50. Hutchinson, K. L.; Peters, C. J.; Nichol, S. T. Sin Nombre virus mRNA synthesis. Virology 1996, 224, 139-149.
51. Salomon, R.; Franks, J.; Govorkova, E. A.; Ilyushina, N. A.; Yen, H. L.; et al. The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04. J. Exp. Med. 2006, 203, 689-697.
52. Tomassini, J.; Selnick, H.; Davies, M. E.; Armstrong, M. E.; Baldwin, J.; et al. Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2, 4-dioxobutanoic acid compounds. Antimi-crob. Agents Chemother. 1994, 38, 2827-2837.
53. Eriksson, B.; Helgstrand, E.; Johansson, N. G.; Larsson, A.; Misiorny, A.; et al. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 1977, 11, 946-951.
54. Furuta, Y.; Takahashi, K.; Kuno-Maekawa, M.; Sangawa, H.; Uehara, S.; et al. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 2005, 49, 981-986.
55. Portela, A.; Digard, P. The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J. Gen. Virol. 2002, 83, 723-734.
56. Elton, D.; Medcalf, E.; Bishop, K.; Digard, P. Oligomerization of the influenza virus nucleoprotein: Identification of positive and negative sequence elements. Virology 1999, 260, 190-200.
57. Elton, D.; Medcalf, L.; Bishop, K.; Harrison, D.; Digard, P. Identification of amino acid residues of influenza virus nucleoprotein essential for RNA binding. J. Virol. 1999, 73, 7357-7367.
58. Area, E.; Martin-Benito, J.; Gastaminza, P.; Torreira, E.; Valpuesta, J. M.; et al. 3D structure of the influenza virus polymerase complex: Localization of subunit domains. Proc. Natl. Acad. Sci. USA 2004, 101, 308-313.
59. Rowe, T.; Abernathy, R. A.; Hu-Primmer, J.; Thompson, W. W.; Lu, X.; et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol. 1999, 37, 937-943.
60. Shu, L. L.; Bean, W. J.; Webster, R. G. Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990. J. Virol. 1993, 67, 2723-2729.
61. Tumpey, T. M.; Alvarez, R.; Swayne, D. E.; Suarez, D. L. Diagnostic approach for differentiating infected from vaccinated poultry on the basis of antibodies to NS1, the nonstructural protein of influenza A virus. J. Clin. Microbiol. 2005, 43, 676-683.
62. Davey, J.; Colman, A.; Dimmock, N. J. Location of influenza virus M, NP and NS1 proteins in microinjected cells. J. Gen. Virol. 1985, 66(Pt. 11), 2319-2334.
63. Noah, D. L.; Twu, K. Y.; Krug, R. M. Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3' end processing of cellular pre-mRNAS. Virology 2003, 307, 386-395.
64. Min, J. Y.; Krug, R. M. The primary function of RNA binding by the influenza A virus NS1 protein in infected cells: Inhibiting the 2'5' oligo (A) synthetase/RNase L pathway. Proc. Natl. Acad. Sci. USA 2006, 103, 7100-7105.
65. Li, S.; Min, J. Y.; Krug, R. M.; Sen, G. C. Binding of the influenza A virus NS1 protein to PKR mediates the inhibition of its activation by either PACT or double-stranded RNA. Virology 2006, 349, 13-21.
66. Li, Z.; Jiang, Y.; Jiao, P.; Wang, A.; Zhao, F.; et al. The NS1 gene contributes to the virulence of H5N1 avian influenza viruses. J. Virol. 2006, 80, 11115-11123.
67. Qian, X. Y.; Chien, C. Y.; Lu, Y.; Montelione, G. T.; Krug, R. M. An amino-terminal polypeptide fragment of the influenza virus NS1 protein possesses specific RNA-binding activity and largely helical backbone structure. RNA 1995, 1, 948-956.
68. Neumann, G.; Watanabe, T.; Ito, H.; Watanabe, S.; Goto, H.; et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. USA 1999, 96, 9345-9350.
69. Donelan, N. R.; Basler, C. F.; Garcia-Sastre, A. A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J. Virol. 2003, 77, 13257-13266.
70. Krug, R. M.; Yuan, W.; Noah, D. L.; Latham, A. G. Intracellular warfare between human influenza viruses and human cells: The roles of the viral NS1 protein. Virology 2003, 309, 181-189.
71. O'Neill, R. E.; Talon, J.; Palese, P. The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. EMBO J. 1998, 17, 288-296.
72. Henklein, P.; Bruns, K.; Nimtz, M.; Wray, V.; Tessmer, U.; et al. Influenza A virus protein PB1-F2: Synthesis and characterization of the biologically active full length protein and related peptides. J. Pept. Sci. 2005, 11, 481-490.
73. Chen, W.; Calvo, P. A.; Malide, D.; Gibbs, J.; Schubert, U.; et al. A novel influenza A virus mitochondrial protein that induces cell death. Nat. Med. 2001, 7, 1306-1312.
74. Yamada, H.; Chounan, R.; Higashi, Y.; Kurihara, N.; Kido, H. Mitochondrial targeting sequence of the influenza A virus PB1-F2 protein and its function in mitochondria. FEBS Lett. 2004, 578, 331-336.
75. Noah, J. W., Severson, W., Noah, D. L., Rasmussen, L., White, E. L., Jonsson, C. B. A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Res. 2006, doi:10.1016/j.antiviral.2006.07.006.
76. Zhang, J. H.; Chung, T. D.; Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999, 4, 67-73.
77. Zhang, A.; Jin, M.; Liu, F.; Guo, X.; Hu, Q.; et al. Development and evaluation of a DAS-ELISA for rapid detection of avian influenza viruses. Avian Dis. 2006, 50, 325-330.
78. Starick, E.; Werner, O.; Schirrmeier, H.; Kollner, B.; Riebe, R.; et al. Establishment of a competitive ELISA (cELISA) system for the detection of influenza A virus nucleoprotein antibodies and its application to field sera from different species. J. Vet. Med. B. Infect. Dis. Vet. Public Health 2006, 53, 370-375.
79. Bai, G. R.; Sakoda, Y.; Mweene, A. S.; Fujii, N.; Minakawa, H.; et al. Improvement of a rapid diagnosis kit to detect either influenza A or B virus infections. J. Vet. Med. Sci. 2006, 68, 35-40.
80. Woolcock, P. R.; Cardona, C. J. Commercial immunoassay kits for the detection of influenza virus type A: evaluation of their use with poultry. Avian Dis. 2005, 49, 477-481.
81. Crossley, B. M.; Hietala, S. K.; Shih, L. M.; Lee, L.; Skowronski, E. W.; et al. High-throughput real-time RT-PCR assay to detect the exotic Newcastle Disease Virus during the California 2002-2003 outbreak. J. Vet. Diagn. Invest. 2005, 17, 124-132.
82. Stevens, J.; Blixt, O.; Glaser, L.; Taubenberger, J. K.; Palese, P.; et al. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J. Mol. Biol. 2006, 355, 1143-1155.
83. Dawson, E. D.; Moore, C. L.; Smagala, J. A.; Dankbar, D. M.; Mehl-mann, M.; et al. MChip: A Tool for Influenza Surveillance. Anal. Chem. 2006, 78, 7610-7615.
84. Townsend, M. B.; Dawson, E. D.; Mehlmann, M.; Smagala, J. A.; Dankbar, D. M.; et al. Experimental evaluation of the FluChip diagnostic microarray for influenza virus surveillance. J. Clin. Microbiol. 2006, 44, 2863-2871.
85. World Health Organization. WHO activities in avian influenza and pandemic influenza preparedness. In Epidemic and Pandemic Alert and Response, January-May 2006.
86. Qiao, C.; Tian, G.; Jiang, Y.; Li, Y.; Shi, J.; et al. Vaccines developed for h5 highly pathogenic avian influenza in china. Ann. N. Y. Acad. Sci. 2006, 1081, 182-192.
87. Treanor, J. J.; Campbell, J. D.; Zangwill, K. M.; Rowe, T.; Wolff, M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 2006, 354, 1343-1351.
88. World Health Organization. (http://www.who.int/csr/disease/avian_ influenza/country/cases_table_2006_11_29/en/index.html). 2006.
89. Bateman, J. B.; Davis, M. S.; McCaffrey, P. A. Rate of reaction of red blood cells with influenza virus hemagglutinin. Am. J. Hyg. 1955, 62, 342-348.
90. Auewarakul, P.; Kositanont, U.; Sornsathapornkul, P.; Tothong, P.; Kanyok, R.; et al. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 2006.
91. Stephenson, I.; Wood, J. M.; Nicholson, K. G.; Charlett, A.; Zambon, M. C. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res. 2004, 103, 91-95.
92. Noah, D. L. Unpublished data.
93. Reynolds, M. G.; Anh, B. H.; Thu, V. H.; Montgomery, J. M.; Bausch, D. G.; et al. Factors associated with nosocomial SARS-CoV transmission among healthcare workers in Hanoi, Vietnam, 2003. BMC Public Health 2006, 6, 207.
94. Choi, K. S.; Ko, Y. J.; Nah, J. J.; Kim, Y. J.; Kang, S. Y.; Yoon, K. J.; Joo, Y. S. Monoclonal antibody-based competitive enzyme-linked immunosorbent assay for detecting and quantifying West Nile virus-neutralizing antibodies in horse sera. Clin. Vaccine Immunol. 2007, 14, 134-138.
95. Gupta, C. K.; Leszczynski, J.; Gupta, R. K.; Siber, G. R. An enzyme immunoassay based micro-neutralization test for titration of antibodies to human cytomegalovirus (CMV) and its correlation with direct ELISA measuring CMV IgG antibodies. Biologicals 1996, 24, 41-49.
96. Sidwell, R. W.; Smee, D. F. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res. 2000, 48, 1-16.
97. Gubareva, L. V.; Webster, R. G.; Hayden, F. G. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimi-crob. Agents Chemother. 2001, 45, 3403-3408.
98. Zhou, G.; Ferrer, M.; Chopra, R.; Kapoor, T. M.; Strassmaier, T.; et al. The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core. Bioorg. Med. Chem. 2000, 8, 2219-2227.
99. Ferrer, M.; Kapoor, T. M.; Strassmaier, T.; Weissenhorn, W.; Skehel, J. J.. et al. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat. Struct. Biol. 1999, 6, 953-960.
100. Fox, S.; Farr-Jones, S.; Sopchak, L.; Boggs, A.; Nicely, H. W.; et al. High-throughput screening: update on practices and success. J. Biomol. Screen. 2006, 11, 864-869.
101. Westby, M.; Nakayama, G. R.; Butler, S. L.; Blair, W. S. Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitors. Antiviral Res. 2005, 67, 121-140.
102. Shoichet, B. K. Screening in a spirit haunted world. Drug Discov. Today 2006, 11, 607-615.
103. Severson, W. E., and Jonsson, C. B. Unpublished data.
104. Digan, M. E.; Pou, C.; Niu, H.; Zhang, J. H. Evaluation of division-arrested cells for cell-based high-throughput screening and profiling. J. Biomol. Screen. 2005, 10, 615-623.
105. McCoy, M. H.; Wang, E. Use of electric cell-substrate impedance sensing as a tool for quantifying cytopathic effect in influenza A virus infected MDCK cells in real-time. J. Virol. Methods 2005, 130, 157-161.
106. Smee, D. F.; Morrison, A. C.; Barnard, D. L.; Sidwell, R. W. Comparison of colorimetric, fluorometric, and visual methods for determining antiinfluenza (H1N1 and H3N2) virus activities and toxicities of compounds. J. Virol. Methods 2002, 106, 71-79.
107. Noah, J. W. Unpublished data.
108. Giffin, K.; Rader, R. K.; Marino, M. H.; Forgey, R. W. Novel assay for the influenza virus M2 channel activity. FEBS Lett. 1995, 357, 269-274.
109. Mould, J. A.; Drury, J. E.; Frings, S. M.; Kaupp, U. B.; Pekosz, A.; et al. Permeation and activation of the M2 ion channel of influenza A virus. J. Biol. Chem. 2000, 275, 31038-31050.
110. Invitrogen. Amplex Red neuraminidase (Sialidase) Assay. Molecular Probes 2004, A22178, 1-3.
111. Blick, T. J.; Tiong, T.; Sahasrabudhe, A.; Varghese, J. N.; Colman, P. M.; et al. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 1995, 214, 475-484.
112. Varghese, J. N.; Colman, P. M. Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 Å resolution. J. Mol. Biol. 1991, 221, 473-486.
113. Liu, A.; Cao, H.; Du, G. Drug screening for influenza neuraminidase inhibitors. Sci. China C. Life Sci. 2005, 48, 1-5.
114. Szecsi, J.; Drury, R.; Josserand, V.; Grange, M. P.; Boson, B.; et al. Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions. Mol. Ther. 2006, 14, 735-744.
115. Deng, T.; Sharps, J.; Fodor, E.; Brownlee, G. G. In vitro assembly of PB2 with a PB1-PA dimer supports a new model of assembly of influenza A virus polymerase subunits into a functional trimeric complex. J. Virol. 2005, 79, 8669-8674.
116. Brownlee, G. G.; Sharps, J. L. The RNA polymerase of influenza a virus is stabilized by interaction with its viral RNA promoter. J. Virol. 2002, 76, 7103-7113.
117. Bhat, J.; Rane, R.; Solapure, S. M.; Sarkar, D.; Sharma, U.; Harish, M. N.; Lamb, S.; Plant, D.; Alcock, P.; Peters, S.; Barde, S.; Roy, R. K. High-throughput screening of RNA polymerase inhibitors using a fluorescent UTP analog. J. Biomol. Screen. 2006, 11, 968-976.
118. Wang, Y. K.; Rigat, K. L.; Roberts, S. B.; Gao, M. A homogeneous, solid-phase assay for hepatitis C virus RNA-dependent RNA polymerase. Anal. Biochem. 2006, 359, 106-111.
119. Chien, C. Y.; Xu, Y.; Xiao, R.; Aramini, J. M.; Sahasrabudhe, P. V.; et al. Biophysical characterization of the complex between double-stranded RNA and the N-terminal domain of the NS1 protein from influenza A virus: Evidence for a novel RNA-binding mode. Biochemistry 2004, 43, 1950-1962.
120. Prevention, C.f.D.C.a. http://www.cdc.gov/flu/h2n2backgroundqa.htm. 2006.
121. Ghosh, R. N.; DeBiasio, R.; Hudson, C. C.; Ramer, E. R.; Cowan, C. L.; et al. Quantitative cell-based high-content screening for vasopressin receptor agonists using transfluor technology. J. Biomol. Screen. 2005, 10, 476-484.